184 related articles for article (PubMed ID: 21434688)
1. Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility.
Thompson AA; Jiao GS; Kim S; Thai A; Cregar-Hernandez L; Margosiak SA; Johnson AT; Han GW; O'Malley S; Stevens RC
Biochemistry; 2011 May; 50(19):4019-28. PubMed ID: 21434688
[TBL] [Abstract][Full Text] [Related]
2. 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.
Dickerson TJ; Smith GR; Pelletier JC; Reitz AB
Curr Top Med Chem; 2014; 14(18):2094-102. PubMed ID: 25335884
[TBL] [Abstract][Full Text] [Related]
3. Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease.
Stowe GN; Silhár P; Hixon MS; Silvaggi NR; Allen KN; Moe ST; Jacobson AR; Barbieri JT; Janda KD
Org Lett; 2010 Feb; 12(4):756-9. PubMed ID: 20092262
[TBL] [Abstract][Full Text] [Related]
4. Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding.
Burnett JC; Schmidt JJ; McGrath CF; Nguyen TL; Hermone AR; Panchal RG; Vennerstrom JL; Kodukula K; Zaharevitz DW; Gussio R; Bavari S
Bioorg Med Chem; 2005 Jan; 13(2):333-41. PubMed ID: 15598556
[TBL] [Abstract][Full Text] [Related]
5. Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity.
Masuyer G; Zhang S; Barkho S; Shen Y; Henriksson L; Košenina S; Dong M; Stenmark P
Sci Rep; 2018 Mar; 8(1):4518. PubMed ID: 29540745
[TBL] [Abstract][Full Text] [Related]
6. Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.
Jacobson AR; Adler M; Silvaggi NR; Allen KN; Smith GM; Fredenburg RA; Stein RL; Park JB; Feng X; Shoemaker CB; Deshpande SS; Goodnough MC; Malizio CJ; Johnson EA; Pellett S; Tepp WH; Tzipori S
Toxicon; 2017 Oct; 137():36-47. PubMed ID: 28698055
[TBL] [Abstract][Full Text] [Related]
7. Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the β-exosite.
Smith GR; Caglič D; Capek P; Zhang Y; Godbole S; Reitz AB; Dickerson TJ
Bioorg Med Chem Lett; 2012 Jun; 22(11):3754-7. PubMed ID: 22542019
[TBL] [Abstract][Full Text] [Related]
8. Superactivation of the botulinum neurotoxin serotype A light chain metalloprotease: a new wrinkle in botulinum neurotoxin.
McAllister LA; Hixon MS; Kennedy JP; Dickerson TJ; Janda KD
J Am Chem Soc; 2006 Apr; 128(13):4176-7. PubMed ID: 16568962
[TBL] [Abstract][Full Text] [Related]
9. The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.
Mizanur RM; Frasca V; Swaminathan S; Bavari S; Webb R; Smith LA; Ahmed SA
J Biol Chem; 2013 Aug; 288(33):24223-33. PubMed ID: 23779108
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors.
Thompson JC; Dao WT; Ku A; Rodriguez-Beltran SL; Amezcua M; Palomino AY; Lien T; Salzameda NT
Bioorg Med Chem; 2020 Sep; 28(18):115659. PubMed ID: 32828426
[TBL] [Abstract][Full Text] [Related]
11. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
Lam KH; Sikorra S; Weisemann J; Maatsch H; Perry K; Rummel A; Binz T; Jin R
Pathog Dis; 2018 Jun; 76(4):. PubMed ID: 29688327
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the functional activity of botulinum neurotoxin subtype B6.
Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.
Li B; Cardinale SC; Butler MM; Pai R; Nuss JE; Peet NP; Bavari S; Bowlin TL
Bioorg Med Chem; 2011 Dec; 19(24):7338-48. PubMed ID: 22082667
[TBL] [Abstract][Full Text] [Related]
14. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.
Ambrin G; Kumar R; Singh BR
Toxicon; 2018 Mar; 144():34-41. PubMed ID: 29309744
[TBL] [Abstract][Full Text] [Related]
15. Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.
Gul N; Smith LA; Ahmed SA
PLoS One; 2010 Sep; 5(9):e12872. PubMed ID: 20877571
[TBL] [Abstract][Full Text] [Related]
16. Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E.
Chen S; Barbieri JT
J Biol Chem; 2007 Aug; 282(35):25540-7. PubMed ID: 17609207
[TBL] [Abstract][Full Text] [Related]
17. Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling.
Kumar G; Kumaran D; Ahmed SA; Swaminathan S
Acta Crystallogr D Biol Crystallogr; 2012 May; 68(Pt 5):511-20. PubMed ID: 22525749
[TBL] [Abstract][Full Text] [Related]
18. Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay.
James NG; Malik S; Sanstrum BJ; Rhéaume C; Broide RS; Jameson DM; Brideau-Andersen A; Jacky BS
Sci Rep; 2021 Apr; 11(1):7832. PubMed ID: 33837264
[TBL] [Abstract][Full Text] [Related]
19. Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.
Silvaggi NR; Boldt GE; Hixon MS; Kennedy JP; Tzipori S; Janda KD; Allen KN
Chem Biol; 2007 May; 14(5):533-42. PubMed ID: 17524984
[TBL] [Abstract][Full Text] [Related]
20. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B.
Swaminathan S; Eswaramoorthy S
Nat Struct Biol; 2000 Aug; 7(8):693-9. PubMed ID: 10932256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
